Abeona Therapeutics Inc. (ABEO)
NASDAQ$5.29
Market Cap
$229.96M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
264 of 924
Rank in Industry
151 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ABEO Insider Trading Activity
ABEO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $154,036 | 5 | 56 |
Sells | $275,137 | 4 | 44 |
Related Transactions
| Alland Leila | director | 1 | $51,799 | 0 | $0 | $51,799 |
| Seshadri Vishwas | Chief Executive Officer | 1 | $32,000 | 0 | $0 | $32,000 |
| O'Malley Brendan M. | SVP, General Counsel | 1 | $27,864 | 0 | $0 | $27,864 |
| Charles Faith L. | director | 1 | $24,764 | 0 | $0 | $24,764 |
| Vazzano Joseph Walter | Chief Financial Officer | 1 | $17,609 | 0 | $0 | $17,609 |
| Silverstein Christine Berni | director | 0 | $0 | 1 | $116,453 | $-116,453 |
| Alvino Mark | director | 0 | $0 | 3 | $158,684 | $-158,684 |
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye …
Insider Activity of Abeona Therapeutics Inc.
Over the last 12 months, insiders at Abeona Therapeutics Inc. have bought $154,036 and sold $275,137 worth of Abeona Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Abeona Therapeutics Inc. have bought $134,796 and sold $1.08M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Alland Leila (director) — $51,799. Seshadri Vishwas (Chief Executive Officer) — $32,000. O'Malley Brendan M. (SVP, General Counsel) — $27,864.
The last purchase of 11,000 shares for transaction amount of $51,799 was made by Alland Leila (director) on 2024‑05‑16.
List of Insider Buy and Sell Transactions, Abeona Therapeutics Inc.
| 2025-01-29 | Sale | Alvino Mark | director | 4,000 0.0092% | $5.38 | $21,520 | +0.92% | |
| 2025-01-21 | Sale | Alvino Mark | director | 4,000 0.0091% | $5.10 | $20,400 | +5.01% | |
| 2024-06-18 | Sale | Silverstein Christine Berni | director | 25,821 0.0635% | $4.51 | $116,453 | +23.68% | |
| 2024-06-18 | Sale | Alvino Mark | director | 25,890 0.0637% | $4.51 | $116,764 | +23.68% | |
| 2024-05-16 | Alland Leila | director | 11,000 0.0286% | $4.71 | $51,799 | +20.76% | ||
| 2024-04-26 | Charles Faith L. | director | 7,550 0.0265% | $3.28 | $24,764 | +68.71% | ||
| 2024-04-25 | Seshadri Vishwas | Chief Executive Officer | 10,000 0.0343% | $3.20 | $32,000 | +72.41% | ||
| 2024-04-25 | Vazzano Joseph Walter | Chief Financial Officer | 5,608 0.0189% | $3.14 | $17,609 | +72.41% | ||
| 2024-04-25 | O'Malley Brendan M. | SVP, General Counsel | 8,600 0.0299% | $3.24 | $27,864 | +72.41% | ||
| 2024-02-06 | Seshadri Vishwas | Chief Executive Officer | 20,000 0.0784% | $4.39 | $87,800 | +32.33% | ||
| 2024-01-17 | Sale | Alvino Mark | director | 7,084 0.0285% | $5.11 | $36,199 | +9.53% | |
| 2023-09-27 | Sale | Amoroso Michael | director | 5,508 0.022% | $3.91 | $21,542 | +21.97% | |
| 2023-09-27 | Sale | Silverstein Christine Berni | director | 6,330 0.0252% | $3.91 | $24,721 | +21.97% | |
| 2023-09-27 | Sale | Alland Leila | director | 7,246 0.0288% | $3.90 | $28,270 | +21.97% | |
| 2023-09-27 | Sale | Charles Faith L. | director | 8,330 0.0417% | $4.91 | $40,924 | +21.97% | |
| 2023-09-27 | Sale | Alvino Mark | director | 6,316 0.0252% | $3.91 | $24,724 | +21.97% | |
| 2023-09-27 | Seshadri Vishwas | Chief Executive Officer | 20,000 0.083% | $4.07 | $81,400 | +21.97% | ||
| 2023-09-20 | Sale | Amoroso Michael | director | 327 0.0014% | $3.90 | $1,275 | +25.79% | |
| 2023-09-19 | Vazzano Joseph Walter | Chief Financial Officer | 3,000 0.0122% | $3.82 | $11,458 | +26.12% | ||
| 2023-09-18 | O'Malley Brendan M. | SVP, General Counsel | 3,000 0.0125% | $3.80 | $11,400 | +30.25% |
Total: 103
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Seshadri Vishwas | Chief Executive Officer | 538260 1.2382% | $2.85M | 3 | 0 | +27.15% |
| Vazzano Joseph Walter | Chief Financial Officer | 233868 0.538% | $1.24M | 3 | 0 | +3.41% |
| O'Malley Brendan M. | SVP, General Counsel | 188718 0.4341% | $998,318.22 | 4 | 5 | +5.36% |
| Alland Leila | director | 82857 0.1906% | $438,313.53 | 1 | 1 | |
| Charles Faith L. | director | 78323 0.1802% | $414,328.67 | 1 | 1 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$21,574,635 | 88 | 2.81% | $217.93M | |
$7,150,333 | 87 | -8.28% | $207.01M | |
$69,130,029 | 69 | 25.63% | $240.78M | |
$11,468,215 | 44 | 17.78% | $246.73M | |
$48,218,096 | 42 | 0.89% | $204.72M |
ABEO Institutional Investors: Active Positions
| Increased Positions | 31 | +54.39% | 3M | +9.82% |
| Decreased Positions | 18 | -31.58% | 941,288 | -3.27% |
| New Positions | 15 | New | 572,147 | New |
| Sold Out Positions | 4 | Sold Out | 63,983 | Sold Out |
| Total Postitions | 70 | +22.81% | 31M | +6.55% |
ABEO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Adage Capital Partners Gp, L.L.C. | $20,448.00 | 9.07% | 3.9M | +652,366 | +20.07% | 2024-12-31 |
| Suvretta Capital Management, Llc | $19,312.00 | 8.57% | 3.69M | 0 | 0% | 2024-12-31 |
| Nantahala Capital Management, Llc | $18,493.00 | 8.21% | 3.53M | +96,577 | +2.81% | 2024-12-31 |
| Millennium Management Llc | $11,094.00 | 4.92% | 2.12M | -184,459 | -8.01% | 2024-12-31 |
| Western Standard Llc | $10,922.00 | 4.85% | 2.08M | +386,321 | +22.75% | 2024-12-31 |
| Vanguard Group Inc | $10,302.00 | 4.57% | 1.97M | -41,603 | -2.07% | 2024-12-31 |
| Vivo Capital, Llc | $9,656.00 | 4.29% | 1.84M | 0 | 0% | 2024-12-31 |
| Rosalind Advisors, Inc. | $9,460.00 | 4.2% | 1.81M | -26,610 | -1.45% | 2024-12-31 |
| Laurion Capital Management Lp | $6,847.00 | 3.04% | 1.31M | 0 | 0% | 2024-12-31 |
| 683 Capital Management, Llc | $4,149.00 | 1.84% | 791,845 | +116,845 | +17.31% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.